The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.
The investigators will test the primary hypothesis that recurrence-free survival after esophageal cancer surgery is longer in patients randomized to propofol-based total intravenous anesthesia than to volatile sevoflurane anesthesia. The investigators will test the secondary hypotheses that propofol-based total intravenous anesthesia: 1) speeds discharge from the ICU; 2) speeds discharge from the hospital; and, 3) improves the quality of recovery, as assessed by QoR-15 on postoperative day 2.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,614
Propofol-based total intravenous anesthesia, titrated to clinical need.
Sevoflurane intravenous anesthesia, titrated to clinical need.
Shanhai Chest Hospital
Shanghai, China
RECRUITINGRecurrence-free survival
Patients who did not experience cancer recurrence and/or death.
Time frame: 4 years
ICU duration
Postoperative time in ICU during initial admission.
Time frame: From ICU admission until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 100 months
Hospital duration
Postoperative time spent in hospital during initial admission.
Time frame: Up to 100 months
QoR-15
Quality of Recovery 15 score on postoperative day 2.
Time frame: 2 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.